Loading clinical trials...

Diuretic Testing in Chronic Kidney Disease | Clinical Trials | Clareo Health

RECRUITINGNA

Diuretic Testing in Chronic Kidney Disease

NCT06841692•Erasmus Medical Center

Summary

The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are: Does a worse result of a diuretic test predict the progression of chronic kidney disease? If there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney. Participants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit
•eGFR within the expected range for age (a decline of 1 ml/min/1.73 m2 per year starting from age 40 is considered the normal age-related decline in kidney function

Exclusion Criteria

•Known intolerance or allergy to the diuretics
•Current systemic chemotherapy for malignancy
•Kidney transplant recipient
•Use of calcineurin-inhibitors
•Life expectancy \< 12 months
•Current immunosuppressive treatment for glomerulonephritis
•Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team
•Hypokalemia or hyperkalemia (K+ \< 3.0mmol/L or K+ \> 5.5 mmol/L) at inclusion visit
•Hypo- or hypernatremia (Na+ \< 130 mmol/L or Na+ \> 150mmol/L) at inclusion visit
•Inherited tubulopathy as the cause of CKD
+9 more criteria

Locations (1)

Erasmus MC

Rotterdam, South Holland, Netherlands

Key Dates

Start Date

April 1, 2025

Primary Completion Date

October 31, 2029

Completion Date

October 31, 2029

Last Updated

August 7, 2025

Enrollment

ESTIMATED participants

Conditions

Kidney Disease, Chronic

Interventions

Diuretic Testing

DIAGNOSTIC_TEST

Contacts

Sebastian B Beckmann, MD

CONTACT

+31 6 39022349 s.beckmann@erasmusmc.nl

Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION)

NCT07374042

Kidney Disease, Chronic

View study

RECRUITINGNA

A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)

NCT06343727

Kidney FailureFrailty+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Diuretic Testing in Chronic Kidney Disease

Inclusion Criteria

Exclusion Criteria

Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION)

A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)

Rutgers University Study of the Genetics of Kidney Disease

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

Monitoring of the Sympathetic/Vagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)

An Observational Study of Patients With Chronic Kidney Disease